Australia discusses scrapping fee exemption scheme for medtech and pharma
This article was originally published in Clinica
Executive Summary
Australia's Therapeutic Goods Administration is considering whether to retain, replace or scrap its scheme for allowing medtech and phama companies to apply for an exemption from the annual charge for maintaining product entries on the Australian Register of Therapeutic that have a low-value turnover.